Eltrombopag Polpharma

Leaflet accompanying the packaging: information for the user

Eltrombopag Polpharma, 12.5 mg, film-coated tablets

Eltrombopag Polpharma, 25 mg, film-coated tablets

Eltrombopag Polpharma, 50 mg, film-coated tablets

Eltrombopag Polpharma, 75 mg, film-coated tablets

Eltrombopag

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What is Eltrombopag Polpharma and what is it used for
• 2. Important information before taking Eltrombopag Polpharma
• 3. How to take Eltrombopag Polpharma
• 4. Possible side effects
• 5. How to store Eltrombopag Polpharma
• 6. Contents of the packaging and other information

1. What is Eltrombopag Polpharma and what is it used for

Eltrombopag Polpharma contains eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists. The medicine is used to increase the number of platelets in the patient's blood. Platelets are blood components that help reduce the risk of bleeding or prevent it. Eltrombopag Polpharma is used to treat a bleeding disorder called primary immune thrombocytopenia (ITP) in patients over 1 year of age who have been previously treated with other medicines (corticosteroids or immunoglobulins) and have not responded to them. Primary immune thrombocytopenia is caused by a low platelet count (thrombocytopenia). People with primary immune thrombocytopenia are more prone to bleeding. Symptoms that patients with primary immune thrombocytopenia may notice include petechiae (small, flat, red spots under the skin), purpura, nosebleeds, gum bleeding, and inability to stop bleeding in case of injury or trauma. Eltrombopag Polpharma may also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infection who have had difficulty due to side effects during treatment with interferon. Many people with hepatitis C have a low platelet count, not only due to the disease but also as a result of the action of some antiviral drugs used in its treatment. Taking Eltrombopag Polpharma may help patients complete full treatment with antiviral drugs (peginterferon and ribavirin).

2. Important information before taking Eltrombopag Polpharma

When not to take Eltrombopag Polpharma

• -if the patient is allergic to eltrombopag or any of the other ingredients of this medicine (listed in section 6 under "What Eltrombopag Polpharma contains"). The patient should consult a doctor if they think they have this condition.

Warnings and precautions

Before starting treatment with Eltrombopag Polpharma, the patient should discuss the following with their doctor:

• if the patient has liver disease. People with low platelet count and advanced (long-standing) liver disease are at higher risk of side effects, including life-threatening liver damage and blood clots. If the doctor considers that the benefits of taking Eltrombopag Polpharma outweigh the risks, the patient will be closely monitored during treatment.
• if the patient has a risk of blood clots in the veins or arteries, or if there is a family history of blood clots.

The risk of blood clots may be increased:

• if the patient is elderly
• if the patient has been immobilized for a long time
• if the patient has cancer
• if the patient is taking oral contraceptives or hormone replacement therapy
• if the patient has recently undergone surgery or had an injury
• if the patient is overweight
• if the patient smokes
• if the patient has advanced chronic liver disease. The patient should inform their doctor before starting treatmentif any of the above conditions apply to them. The patient should not take Eltrombopag Polpharma unless the doctor considers that the expected benefits outweigh the risk of blood clots.
• if the patient has cataracts(clouding of the lens in the eye)
• if the patient has other blood disorders, such as myelodysplastic syndrome (MDS). Before starting treatment with Eltrombopag Polpharma, the doctor will perform tests to rule out this condition. If the patient has MDS and takes Eltrombopag Polpharma, MDS may worsen.

The patient should inform their doctor if any of the above situations apply to them.

Eye examination

The doctor will recommend an eye examination to detect cataracts. If the patient does not undergo regular eye examinations, the doctor should recommend regular examinations. The occurrence of any bleeding in the retina (the layer of light-sensitive cells at the back of the eye) or near it may also be examined.

Regular tests will be necessary

Before starting treatment with Eltrombopag Polpharma, the doctor will perform blood tests to assess blood cells, including platelets. During treatment, these tests will be repeated at regular intervals.

Blood tests for liver function

Eltrombopag Polpharma may cause changes in blood test results that may indicate liver damage - increased activity of certain liver enzymes, in particular bilirubin and transaminases. If the patient is taking interferon-based treatment with Eltrombopag Polpharma for low platelet count associated with hepatitis C, some liver diseases may worsen. Blood tests to assess liver function will be performed before starting treatment with Eltrombopag Polpharma and at regular intervals during treatment. It may be necessary to stop taking Eltrombopag Polpharma if the levels of these substances increase too much or if other symptoms of liver damage occur. The patient should read the information in section 4 of this leaflet "Liver disorders".

Platelet count tests

If the patient stops taking Eltrombopag Polpharma, it is likely that the low platelet count will return within a few days. The doctor will monitor the patient's platelet count and discuss appropriate precautions with them. A very high platelet count may increase the risk of blood clots. However, blood clots can also occur when the platelet count is normal or too low. The doctor will adjust the dose of Eltrombopag Polpharma to prevent the platelet count from becoming too high. The patient should seek immediate medical attentionif they experience any of the following symptoms of a blood clot:

• swelling, pain, or tenderness in one leg
• sudden shortness of breath, especially with sudden chest pain or rapid breathing
• abdominal pain, abdominal enlargement, blood in the stool.

Bone marrow tests

In patients with bone marrow disorders, medicines like Eltrombopag Polpharma may worsen these disorders. Changes in the bone marrow may be indicated by abnormal blood test results. The doctor may order bone marrow tests during treatment with Eltrombopag Polpharma.

Tests to detect gastrointestinal bleeding

If the patient is taking interferon-based treatment with Eltrombopag Polpharma, they will be monitored for symptoms of gastrointestinal bleeding after stopping treatment with Eltrombopag Polpharma.

Heart tests

The doctor may decide to perform a heart test on the patient during treatment with Eltrombopag Polpharma and perform an electrocardiogram (ECG).

Elderly patients (65 years and older)

There is limited data on the use of Eltrombopag Polpharma in patients aged 65 and older. Caution should be exercised when taking Eltrombopag Polpharma in patients aged 65 and older.

Children and adolescents

Eltrombopag Polpharma is not recommended for children under 1 year of age with primary immune thrombocytopenia. The medicine is also not recommended for patients under 18 years of age with low platelet count associated with hepatitis C virus infection.

Eltrombopag Polpharma and other medicines

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. This includes medicines available without a prescription and vitamins. Some commonly used medicines interact with Eltrombopag Polpharma- including both prescription and non-prescription medicines and products containing minerals. These include:

• antacids used to treat indigestion, heartburn, stomach ulcers(see also "When to take the medicine" in section 3)
• statins, which lower cholesterol levels
• certain medicines used to treat HIV infection, such as lopinavir and ritonavir
• cyclosporine used in transplantsor immune system disorders
• mineral products, such as iron, calcium, magnesium, aluminum, selenium, and zinc, which may be components of vitamin and mineral supplements(see also "When to take the medicine" in section 3)
• medicines such as methotrexate and topotecan, used to treat cancer.

The patient should consult their doctor if they are taking any of the above medicines. Some of them should not be taken while taking Eltrombopag Polpharma, while others may require a dose adjustment or a change in the timing of taking the medicines. The doctor will review the medicines the patient is taking and recommend changes to the treatment if necessary. If the patient is taking medicines to prevent blood clots, there is an increased risk of bleeding. The doctor will discuss this with the patient. If the patient is taking corticosteroids, danazol, and (or) azathioprine, the doses of these medicines may be reduced or their use may be stopped during concurrent use of Eltrombopag Polpharma.

Taking Eltrombopag Polpharma with food and drink

Eltrombopag Polpharma should not be taken with dairy products or drinks, as the calcium in dairy products affects the absorption of the medicine. For more information, see "When to take the medicine" in section 3.

Pregnancy and breastfeeding

Eltrombopag Polpharma should not be taken during pregnancy, unless the doctor recommends it. The effect of Eltrombopag Polpharma when taken during pregnancy is unknown.

• The patient should inform their doctor if they are pregnant, think they may be pregnant, or plan to have a baby.
• The patient should use appropriate contraceptionwhile taking Eltrombopag Polpharma to prevent pregnancy.
• The patient should inform their doctor if they become pregnant while taking Eltrombopag Polpharma.

The patient should not breastfeed while taking Eltrombopag Polpharma. It is not known whether Eltrombopag Polpharma passes into breast milk. The patient should inform their doctor if they are breastfeedingor plan to breastfeed.

Driving and using machines

Eltrombopag Polpharma may cause dizzinessand other side effects that reduce attention. The patient should not drive or operate machineryunless they are sure that these symptoms do not occur in them.

Eltrombopag Polpharma contains isomalt and sodium

If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking the medicine. The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that the medicine is considered "sodium-free".

3. How to take Eltrombopag Polpharma

This medicine should always be taken exactly as prescribed by the doctor. If the patient has any doubts, they should consult their doctor or pharmacist. The patient should not change the dose or dosing schedule of Eltrombopag Polpharma unless their doctor or pharmacist tells them to do so. While taking Eltrombopag Polpharma, the patient will remain under the care of a doctor with experience in treating the patient's condition.

How much to take

In the case of primary immune thrombocytopenia
Adults and children(aged 6 to 17 years) - the usual starting dose in primary immune thrombocytopenia is one 50 mg tabletof Eltrombopag Polpharma per day. Patients of East Asian/South-East Asian origin may require a lower starting dose of 25 mg. Children (aged 1 to 5 years) - the usual starting dose in primary immune thrombocytopenia is one 25 mg tabletof Eltrombopag Polpharma per day. In the case of hepatitis C
Adults- the usual starting dose in hepatitis C is one 25 mg tabletof Eltrombopag Polpharma per day. In patients of East Asian/South-East Asian origin, treatment should be started with the same dose of 25 mg. The onset of action of Eltrombopag Polpharma may occur after 1 to 2 weeks. Depending on the patient's response to treatment with Eltrombopag Polpharma, the doctor may recommend a change in the daily dose.

How to take the tablets

The tablets should be swallowed whole with water.

When to take the medicine

The patient should make sure that:

• for 4 hours beforetaking Eltrombopag Polpharma
• and for 2 hours aftertaking Eltrombopag Polpharma, the patient will notconsume the following foods:
• dairy products, such as cheese, butter, yogurt, ice cream
• milkor drinks containing milk, yogurt, or cream
• antacidsused to treat indigestion and heartburn
• vitamin and mineral supplementscontaining iron, calcium, magnesium, aluminum, selenium, and zinc.

If the patient does not follow these recommendations, Eltrombopag Polpharma will not be properly absorbed by the body.

The patient should consult their doctor for more information about the appropriate foods and drinks.

Taking a higher dose of Eltrombopag Polpharma than recommended

The patient should contact their doctor or pharmacist immediately. If possible, they should show them the packaging of the medicine or this leaflet. The patient's condition will be monitored for any side effects and appropriate treatment will be given promptly.

Missing a dose of Eltrombopag Polpharma

The patient should take the next dose at the usual time. The patient should not take more than one dose of Eltrombopag Polpharma per day.

Stopping treatment with Eltrombopag Polpharma

The patient should not stop taking Eltrombopag Polpharma without consulting their doctor. If the doctor recommends stopping treatment, the patient's platelet count will be monitored weekly for four weeks. See also "Bleeding or bruising after stopping treatment" in section 4. If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Eltrombopag Polpharma can cause side effects, although not everybody gets them.

Symptoms to look out for: the patient should see a doctor

In patients taking Eltrombopag Polpharma for primary immune thrombocytopenia or low platelet count associated with hepatitis C, severe side effects may occur. It is essential to inform the doctor about these symptoms. Increased risk of blood clotsSome patients may have an increased risk of blood clots, and medicines like Eltrombopag Polpharma may worsen this condition. Sudden blockage of a blood vessel by a blood clot is an uncommon side effect and may occur in up to 1 in 100 patients.

The patient should seek immediate medical attention if they experience any symptoms of a blood clot, such as:

• swelling, pain, warmth, redness, or tenderness in one leg
• sudden shortness of breath, especially with sudden chest pain or rapid breathing
• abdominal pain, abdominal enlargement, blood in the stool.

Liver disordersEltrombopag Polpharma may cause changes in blood test results that may indicate liver damage. Liver disorders (increased activity of enzymes in blood test results) are common and may occur in up to 1 in 10 patients. Other liver problems are uncommon and may occur in up to 1 in 100 patients. If the patient experiences any of the following symptoms of liver disorders:

• yellowingof the skin or whites of the eyes (jaundice)
• unusually dark urine

The patient should tell their doctor immediately.

Bleeding or bruising after stopping treatmentUsually, within two weeks of stopping Eltrombopag Polpharma, the patient's platelet count returns to the level before starting treatment with Eltrombopag Polpharma. A low platelet count may increase the risk of bleeding or bruising. The doctor will monitor the patient's platelet count for at least 4 weeks after stopping treatment with Eltrombopag Polpharma. The patient should inform their doctorif they experience bruising or bleeding after stopping treatment with Eltrombopag Polpharma. In some patients, gastrointestinal bleedingmay occur after stopping treatment with peginterferon, ribavirin, and Eltrombopag Polpharma. Symptoms include:

• black, tarry stools (a change in stool color, which is an uncommon side effect that may occur in up to 1 in 100 patients)
• blood in the stool
• vomiting blood or coffee-ground-like material.

The patient should tell their doctor immediatelyif they experience any of these symptoms.

The following side effects have been reported in adults with primary immune thrombocytopenia taking eltrombopag:

Very commonside effects (may occur in more than 1 in 10 patients):

• infection of the nose, sinuses, throat, and upper respiratory tract, upper respiratory tract infection
• cough, common cold
• nausea, diarrhea
• back pain.

Very commonside effects that may be detected in blood tests:

• increased activity of liver enzymes (alanine aminotransferase (ALT)).

Commonside effects (may occur in up to 1 in 10 patients):

• flu, herpes, pneumonia, sinusitis, tonsillitis, upper respiratory tract infection, bronchitis, conjunctivitis, toothache, mouth ulcers, gum bleeding, mouth pain, vomiting, abdominal pain, flatulence, constipation
• liver problems
• skin changes, including excessive sweating, itchy rash, red spots, skin changes, hair loss
• muscle pain, muscle spasms, muscle weakness, bone pain
• foamy urine (indicating protein in the urine)
• heavy menstrual bleeding
• high fever, feeling hot, chest pain, feeling weak.

Commonside effects that may be detected in blood tests:

• decreased red blood cell count (anemia), decreased platelet count (thrombocytopenia), decreased white blood cell count, decreased hemoglobin level, increased eosinophil count, increased white blood cell count (leukocytosis)
• increased urea level in the blood, decreased potassium level
• increased activity of liver enzymes (aspartate aminotransferase (AST)),

increased bilirubin level in the blood (a substance produced by the liver)

• increased levels of certain proteins, increased creatinine level
• increased alkaline phosphatase level.

Uncommonside effects (may occur in up to 1 in 100 patients):

• skin infection
• colon cancer
• allergic reaction
• loss of appetite, painful joint swelling caused by uric acid (gout)
• lack of interest, mood changes, crying, which is hard to stop or occurs at an unexpected time
• balance problems, speech problems, and nerve problems, tremors, paralysis of one side of the body, migraine with aura, nerve damage, vasodilation causing headache
• eye problems, including increased tear production, cataracts, retinal bleeding, dry eyes
• rapid or irregular heartbeat, blue discoloration of the skin, cardiovascular problems, which may be symptoms of heart and blood vessel problems, interruption of blood flow to part of the heart
• pain, swelling, and (or) redness in or around a vein, which may be symptoms of a blood clot, blood clot, redness
• sudden shortness of breath, especially with sudden chest pain and (or) rapid breathing, which may be a sign of blood clots in the lungs (see "Increased risk of blood clots" above in section 4), loss of lung function due to blockage of a pulmonary artery, respiratory problems, throat problems
• gastrointestinal problems, including vomiting, abdominal pain, indigestion, constipation, bloating, taste disturbances, hemorrhoids, stomach pain or discomfort, bleeding in the esophagus
• liver problems, including liver tumor, yellowing of the whites of the eyes or skin (jaundice), liver damage caused by taking the medicine (see "Liver disorders" above in section 4)
• skin changes, including discoloration, peeling, redness, itching, excessive sweating, skin growths, nocturnal sweating
• muscle weakness
• kidney problems, including kidney inflammation, frequent urination at night, kidney failure, white blood cells in the urine
• feeling hot, feeling unwell, skin reaction, such as redness or swelling and pain at the injection site, chest pain and discomfort, fluid accumulation in the body or limbs causing swelling
• sunburn.

Uncommonside effects that may be detected in laboratory tests:

• changes in the shape of red blood cells, decreased red blood cell count (anemia) caused by excessive destruction of red blood cells (hemolytic anemia), increased neutrophil count, presence of immature white blood cells, which may indicate certain diseases, increased platelet count, elevated hemoglobin level
• decreased calcium level
• increased urea level in the blood, increased protein level in the urine
• increased albumin level in the blood, increased total protein level, decreased albumin level in the blood, increased pH of the urine.

The following additional side effects have been reported in children (aged 1 to 17 years) with ITP taking eltrombopag:

Very commonside effects (may occur in more than 1 in 10 children):

• infection of the nose, sinuses, throat, and upper respiratory tract, common cold (upper respiratory tract infection)
• cough
• nausea, diarrhea, abdominal pain
• high fever.

Commonside effects (may occur in up to 1 in 10 children):

• sleep problems (insomnia)
• itching or runny nose, sore throat, runny nose, nasal congestion and sneezing, sore nose and throat
• toothache, mouth problems, including dry mouth, mouth pain, tongue sensitivity, gum bleeding, mouth ulcers.

The following side effects have been reported in patients with hepatitis C taking eltrombopag in combination with peginterferon and ribavirin:

Very commonside effects (may occur in more than 1 in 10 patients):

• loss of appetite
• headache
• cough
• nausea, diarrhea
• itching, swelling of the hands or feet, unusual hair loss
• muscle pain, muscle weakness
• fever, feeling tired, flu-like illness, weakness, chills.

Very commonside effects that may be detected in blood tests:

• decreased red blood cell count (anemia).

Commonside effects (may occur in up to 1 in 10 patients):

• urinary tract infections, infection of the nose, sinuses, throat, and upper respiratory tract, common cold (upper respiratory tract infection), bronchitis, sinusitis, pharyngitis, flu-like illness, dry mouth, mouth pain, gum bleeding
• weight loss
• sleep problems, abnormal sleepiness, depression, anxiety
• dizziness, concentration and memory problems, mood changes, liver problems due to brain damage, tingling or numbness of the hands or feet
• eye problems, including cataracts, dry eyes, retinal bleeding, eye pain
• rapid or irregular heartbeat, blue discoloration of the skin
• shortness of breath, coughing up mucus, sore throat, and discomfort when swallowing
• gastrointestinal problems, including vomiting, abdominal pain, indigestion, constipation, bloating, taste disturbances, hemorrhoids, stomach pain or discomfort
• liver problems, including liver tumor, yellowing of the whites of the eyes or skin (jaundice), liver damage caused by taking the medicine (see "Liver disorders" above in section 4)
• skin changes, including rash, dry skin, hives, redness, itching, excessive sweating, skin growths
• joint pain, back pain, bone pain, limb pain (arms, legs, hands, or feet), muscle spasms
• irritability, general feeling of being unwell, skin reaction, such as redness or swelling and pain at the injection site, chest pain and discomfort, fluid accumulation in the body or limbs causing swelling
• depression, anxiety, sleep problems, nervousness.
• fever, headache.

Commonside effects that may be detected in blood tests:

• increased glucose level in the blood, decreased white blood cell count, decreased neutrophil count, decreased albumin level in the blood, decreased hemoglobin level, increased bilirubin level in the blood (a substance produced by the liver), changes in blood clotting enzymes.

Uncommonside effects (may occur in up to 1 in 100 patients):

• stomach flu (gastroenteritis), sore throat
• decreased red blood cell count (anemia) caused by excessive destruction of red blood cells (hemolytic anemia)
• confusion, agitation
• mouth ulcers or blisters, gastritis
• blood clots in the vein that carries blood to the liver (which may cause liver damage and (or) gastrointestinal problems), liver failure
• skin changes, including discoloration, peeling, redness, itching, skin growths, and nocturnal sweating
• blood clotting problems in small blood vessels with kidney failure, painful urination
• rash, bruising at the injection site, chest discomfort
• heart rhythm problems (prolonged QT interval).

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Eltrombopag Polpharma

The medicine should be stored out of sight and reach of children. The patient should not take this medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month. The inscription on the packaging after the abbreviation EXP indicates the expiry date, and after the abbreviation Lot indicates the batch number. There are no special storage instructions for the medicine. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Eltrombopag Polpharma contains

• The active substance of the medicine is eltrombopag olamine. Eltrombopag Polpharma 12.5 mg: each film-coated tablet contains eltrombopag olamine equivalent to 12.5 mg of eltrombopag. Eltrombopag Polpharma 25 mg: each film-coated tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag. Eltrombopag Polpharma 50 mg: each film-coated tablet contains eltrombopag olamine equivalent to 50 mg of eltrombopag. Eltrombopag Polpharma 75 mg: each film-coated tablet contains eltrombopag olamine equivalent to 75 mg of eltrombopag.
• The other ingredients are: microcrystalline cellulose, mannitol, povidone, isomalt (E 953), calcium silicate, sodium carboxymethylcellulose (type A), magnesium stearate (tablet core); hypromellose, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172) (only in 12.5 mg, 25 mg, and 50 mg doses), triacetin (tablet coating).

What Eltrombopag Polpharma looks like and contents of the pack

Eltrombopag Polpharma 12.5 mg is orange to brown, round, biconvex, film-coated tablets with "I" embossed on one side and a diameter of about 5.5 mm. Eltrombopag Polpharma 25 mg is dark pink, round, biconvex, film-coated tablets with "II" embossed on one side and a diameter of about 8 mm. Eltrombopag Polpharma 50 mg is pink, round, biconvex, film-coated tablets with "III" embossed on one side and a diameter of about 10 mm. Eltrombopag Polpharma 75 mg is red to brown, round, biconvex, film-coated tablets with "IV" embossed on one side and a diameter of about 12 mm. Eltrombopag Polpharma 12.5 mg is available in cardboard boxes containing 10, 14, 28, 30, or 84 film-coated tablets in blisters or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1, or 84x1 film-coated tablets in single-dose perforated blisters. Eltrombopag Polpharma 25 mg is available in cardboard boxes containing 10, 14, 28, 30, or 84 film-coated tablets in blisters or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1, or 84x1 film-coated tablets in single-dose perforated blisters. Eltrombopag Polpharma 50 mg is available in cardboard boxes containing 10, 14, 28, 30, or 84 film-coated tablets in blisters or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1, or 84x1 film-coated tablets in single-dose perforated blisters. Eltrombopag Polpharma 75 mg is available in cardboard boxes containing 10, 14, 28, 30, or 84 film-coated tablets in blisters or in cardboard boxes containing 10x1, 14x1, 28x1, 30x1, or 84x1 film-coated tablets in single-dose perforated blisters. Not all pack sizes may be marketed.

Marketing authorization holder

Polpharma S.A., ul. Pelplińska 19, 83-200 Starogard Gdański, tel. +48 22 364 61 01

Manufacturer

Synthon Hispania S.L., Calle De Castello 1, 08330 Sant Boi De Llobregat, Spain; Synthon B.V., Microweg 22, 6545 CM Nijmegen, Netherlands

Date of last revision of the leaflet